Can Nuvation Bio cover its short-term obligations?

Its current ratio is 7.44 — current assets exceed current liabilities.

Where does Nuvation Bio's balance sheet data come from?

Every line is extracted from Nuvation Bio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Nuvation Bio NUVB Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$125.39M-23.6%	$164.09M+65.9%	$98.9M-60.1%	$247.97M+417%	$47.98M+34.3%
Short-term investments	$408.34M+11.8%	$365.13M-18.9%	$450.15M+25.1%	$359.75M-13.0%	$413.7M-11.4%
Accounts receivable, net	$49.82M+81.1%	$27.5M+13.9%	$24.15M+51.5%	$15.94M+19.3%	$13.36M+3.2%
Inventories	$15.84M+38.8%	$11.41M+99.8%	$5.71M—	——	——
Total current assets	$591.53M+3.5%	$571.52M-1.0%	$577.53M-7.3%	$623.21M+31.0%	$475.57M-9.6%
Property and equipment, net	$535K-5.1%	$564K+0.7%	$560K-8.9%	$615K+9.4%	$562K-4.1%
Accumulated depreciation	——	——	——	——	——
Operating lease right-of-use assets	$3.6M-8.2%	$3.92M-9.5%	$4.33M-6.7%	$4.64M-13.0%	$5.33M+122%
Intangible assets, net	$10.76M-4.1%	$11.21M-4.0%	$11.68M-3.8%	$12.15M+175%	$4.41M—
Other non-current assets	$3.82M-49.7%	$7.61M+1.9%	$7.46M+12.8%	$6.62M0.0%	$6.62M+2,387%
Available-for-sale securities	——	——	——	——	——
Total assets	$610.24M+2.6%	$594.82M-1.1%	$601.56M-7.1%	$647.23M+31.4%	$492.49M-8.9%
Accounts payable	$69.69M+20.6%	$57.8M+5.7%	$54.66M+5.8%	$51.68M+49.9%	$34.48M+30.7%
Accrued expenses	$32.86M-27.3%	$45.18M+38.7%	$32.58M+35.8%	$24M+0.4%	$23.89M-27.2%
Deferred revenue	$8.65M+15.1%	$7.52M+11.8%	$6.72M-30.9%	$9.73M-9.7%	$10.77M—
Current portion of long-term debt	$5.79M+1.2%	$5.72M+1.9%	$5.62M+0.6%	$5.58M-1.8%	$5.69M—
Operating lease liabilities, current	$1.84M-2.2%	$1.88M+0.5%	$1.87M+3.5%	$1.81M-4.3%	$1.89M+13.6%
Short-term borrowings	$5.79M+1.2%	$5.72M+1.9%	$5.62M+0.6%	$5.58M-1.8%	$5.69M—
Income taxes payable	——	——	——	——	——
Total current liabilities	$79.52M-3.3%	$82.23M+20.7%	$68.13M+2.7%	$66.36M+25.7%	$52.77M-9.4%
Deferred tax liabilities	——	——	——	——	——
Long-term debt	$47.33M—	——	——	——	——
Operating lease liabilities, non-current	$2.2M-13.5%	$2.54M-14.4%	$2.97M-12.6%	$3.4M-11.5%	$3.84M+296%
Operating Lease Liabilities (Total)	$4.04M-8.7%	$4.42M-8.6%	$4.84M-7.0%	$5.21M-9.1%	$5.73M+118%
Total liabilities	$290.68M+0.5%	$289.11M+4.9%	$275.68M+0.5%	$274.32M+276%	$73.03M-5.0%
Common stock	$1.43B+0.7%	$1.42B+1.2%	$1.4B+0.6%	$1.4B+1.0%	$1.38B+299%
Retained earnings	-$1.11B+0.5%	-$1.12B-3.4%	-$1.08B-5.5%	-$1.02B-6.1%	-$963.98M-5.8%
Accumulated other comprehensive income (loss)	-$1.68M-797%	-$187K-34.5%	-$139K+57.5%	-$327K-160%	$545K-4.9%
Total stockholders' equity	$319.56M+4.5%	$305.72M-6.2%	$325.88M-12.6%	$372.91M-11.1%	$419.46M-9.6%
Total liabilities and stockholders' equity	$610.24M+2.6%	$594.82M-1.1%	$601.56M-7.1%	$647.23M+31.4%	$492.49M-8.9%
Available-for-Sale Debt Securities - Amortized Cost	——	——	——	——	——
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Allowance for Doubtful Accounts	——	——	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	——	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	——	——	——	——	——
Interest Receivable On Marketable Securities Current	——	——	——	——	——
Short- term Investments	$408.34M+11.8%	$365.13M-18.9%	$450.15M+25.1%	$359.75M-13.0%	$413.7M-11.4%
Derivative Assets - Fair Value	——	——	——	——	——
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)	——	——	——	——	——
Capitalized Contract Costs, Net	——	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$3.82M-49.7%	$7.61M+1.9%	$7.46M+12.8%	$6.62M0.0%	$6.62M-2.1%
Investments - Amortized Cost Basis	——	——	——	——	——
Net Investment in Lease	$3.6M-8.2%	$3.92M-9.5%	$4.33M-6.7%	$4.64M-13.0%	$5.33M+122%
Intangible assets — net	$10.76M-4.1%	$11.21M-4.0%	$11.68M-3.8%	$12.15M+175%	$4.41M—
Operating lease right-of-use assets	$3.6M-8.2%	$3.92M-9.5%	$4.33M-6.7%	$4.64M-13.0%	$5.33M+122%
Other non-current assets	$3.82M-49.7%	$7.61M+1.9%	$7.46M+12.8%	$6.62M0.0%	$6.62M-2.1%
Property, plant and equipment at cost	——	——	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$3.6M-8.2%	$3.92M-9.5%	$4.33M-6.7%	$4.64M-13.0%	$5.33M+122%
Software and Technology Licenses, Net	$3.82M-49.7%	$7.61M+1.9%	$7.46M+12.8%	$6.62M0.0%	$6.62M-2.1%
Accrued Royalties (Current)	——	——	——	——	——
Other Commercial Liabilities	$32.86M-27.3%	$45.18M+38.7%	$32.58M+35.8%	$24M+0.4%	$23.89M-27.2%
Accrued Liabilities, Current	$32.86M-27.3%	$45.18M+38.7%	$32.58M+35.8%	$24M+0.4%	$23.89M-27.2%
Liability Related To Revenue Interest Financing Agreement	$7.94M—	——	——	——	——
Warrant Liability Short Term	——	——	——	——	——
Derivative Liabilities - Fair Value	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Professional Service Fees Payable	——	——	——	——	——
Debt Maturity - 2027	——	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	——	——	——	——	——
Deferred Tax Liabilities - Leasing Arrangements	——	——	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Accrued taxes and other expenses	——	——	——	——	——
Deferred income	$151.89M—	——	——	——	——
Secured Debt	——	——	——	——	——
Total debt	$57.15M-0.4%	$57.36M-0.3%	$57.55M-0.4%	$57.76M+406%	$11.41M+28.0%
Unrecognized Tax Benefits	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	——	——	——	——	——
Common Stock Shares Issued	——	——	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1.43B+0.7%	$1.42B+1.2%	$1.4B+0.6%	$1.4B+1.0%	$1.38B+0.7%
Investments - Gross Unrealized Losses	——	——	——	——	——
Unrealized Gains on Investments	——	——	——	——	——
Unrealized Losses on Investments (Before Tax)	——	——	——	——	——
Warrants and Rights Outstanding	——	——	——	——	——
Credit Derivative Maximum Exposure	——	——	——	——	——
Cumulative Cost Basis	——	——	——	——	——
Fair Value Measurement Disclosure	——	——	——	——	——
Gross Assets/Liabilities	——	——	——	——	——
Accounts Receivable, after Allowance for Credit Loss	$22.72M+41.3%	$16.08M+93.2%	$8.32M+209%	$2.69M+558%	$409K—
Accrued Bonuses Current And Noncurrent	——	——	——	——	——
Accrued Compensation and Benefits	——	——	——	——	——
Income taxes payable – long-term	——	——	——	——	——
Professional service fees	——	——	——	——	——
Accrued Professional Fees Current And Noncurrent	——	——	——	——	——
Accrued Royalties	——	——	——	——	——
Accumulated amortization, debt issuance costs	——	——	——	——	——
Accounts Receivable, Allowance for Credit Loss	——	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	——	——	——	——	——
Gross Unrealized Gains	——	——	——	——	——
Total	——	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——	——
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost	——	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Available for sale investments	——	——	——	——	——
Capitalized Contract Cost, Net	——	——	——	——	——
Cash And Cash Equivalents And Marketable Securities	——	——	——	——	——
Changes In Liabilities Classified In Level3Of Fair Value Hierarchy	——	——	——	——	——
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1	——	——	——	——	——
Common stock, shares authorized (in shares)	——	——	——	——	——
Common stock, shares issued (in shares)	——	——	——	——	——
Common Stock, Shares, Outstanding	——	——	——	——	——
Contract With Customer Liabilities Current	$9.74M—	——	——	——	——
Credit Derivative, Maximum Exposure, Undiscounted	——	——	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	——	——	——	——	——
Less than 12 months	——	——	——	——	——
12 months or more	——	——	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	——	——	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss	——	——	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	——	——	——	——	——
Deferred Tax Liabilities, Gross	——	——	——	——	——
Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets Lease Liability	——	——	——	——	——
Deferred Tax Assets, Net	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	——	——	——	——
R&D credit carryforward	——	——	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	——	——	——	——
Other	——	——	——	——	——
Deferred Tax Liabilities, Other	——	——	——	——	——
Derivatives, gross, liabilities	——	——	——	——	——
Intangible Assets Net Of Amortization	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Liability Related To Finance Agreement	——	——	——	——	——
Long Term Debt Maturities Repayments Of Principal	——	——	——	——	——
2028	——	——	——	——	——
2029	——	——	——	——	——
2029	——	——	——	——	——
2030	——	——	——	——	——
2027	——	——	——	——	——
Long Term Debt Repayments Of Principal Imputed Interest	——	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——	——
Revenue Interest Financing Liability Noncurrent	——	——	——	——	——
Total Financial Assets	——	——	——	——	——
Unrecognized tax benefits	——	——	——	——	——
Warrant Liability	$0-100%	$2.87M+64.8%	$1.74M-26.0%	$2.35M-16.2%	$2.8M+36.6%
Warrants And Rights Outstanding	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Nuvation Bio cover its short-term obligations?: Its current ratio is 7.44 — current assets exceed current liabilities.
Where does Nuvation Bio's balance sheet data come from?: Every line is extracted from Nuvation Bio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.